日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial

奥马西他滨和阿扎胞苷治疗未经治疗的骨髓增生异常综合征伴原始细胞增多患者:一项 I/II 期临床试验

Pollyea, Daniel A; Stevens, Brett M; Abbott, Diana; Amaya, Maria; Gutman, Jonathan A; Kent, Andrew; McMahon, Christine; Schwartz, Marc; Smith, Clayton; Dell-Martin, Jessie; Sohalski, Connor; Ellis, Alexandra; Haag, Mary; Schowinsky, Jeffrey; Pan, Zenggang; Patel, Sweta B; Ransom, Monica; Gillen, Austin; Jordan, Craig T; Pietras, Eric M

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

对于新诊断的急性髓系白血病,在可测量的残留病灶指导下,使用高剂量维奈托克治疗后停用阿扎胞苷。

Gutman, Jonathan A; Winters, Amanda; Kent, Andrew; Amaya, Maria; McMahon, Christine; Smith, Clayton; Jordan, Craig T; Stevens, Brett; Minhajuddin, Mohammad; Pei, Shanshan; Schowinsky, Jeffrey; Tobin, Jennifer; O'Brien, Kelly; Falco, Angela; Taylor, Elizabeth; Brecl, Constance; Zhou, Katie; Ho, Phuong; Sohalski, Connor; Dell-Martin, Jessica; Ondracek, Olivia; Abbott, Diana; Pollyea, Daniel A